. Specific TRPV4 channel agonists increase the number of sparklet sites per field of view in native ECs from fourth-order PAs.
. TRPV4 sparklets increase local, but not whole-cell Ca 2+ levels in the ECs.
Changes in fluorescence were recorded in en face fourth-order PAs loaded with fluo-4AM (10 mol/L) in the presence of GSK101 (10 nmol/L). Cyclopiazonic acid (CPA, 20 mol/L) was used in order to eliminate the interference from Ca 2+ release from intracellular stores. A, A greyscale image of a field of view with ~ 15 ECs; the dotted lines indicates the outlines of ECs. Square boxes represent the regions of interest (ROIs) placed at the sparklet sites. B, Representative fluorescence traces of TRPV4 sparklets using square ROIs (left) and whole-cell fluorescence using whole-cell outlines as ROIs (right). C, Averaged increase in fluorescence (arbitrary fluorescence units; AFU) for ROIs placed at sparklet sites and whole cell ROIs following TRPV4
cannel activation with GSK101 (3 nmol/L; left); average spatial spread of sparklets and area encompassed by whole cell outlines (right). Data are presented as mean ± SEM (n=24 sparklet sites and 24 ECs; *P<0.0001 using independent t-test). Localized Ca 2+ influx events through TRPV4 channels (TRPV4 sparklets) were recorded in en face fourthorder PAs from GCaMP2 Cx40 mice. Cyclopiazonic acid (CPA, 20 mol/L) was used to eliminate the interference from Ca 2+ release from the endoplasmic reticulum (ER). Experiments were performed using 3 nmol/L GSK101 to increase the activity of TRPV4 sparklets in PAs from GCaMP2 mice. All-points histograms were constructed from the F/F0 traces and were fit with a multiple Gaussian curve. The quantal levels (single-channel amplitudes) were derived from the peaks of the multiple Gaussian curve. The data were pooled from three PAs. Dotted lines represent the quantal levels (number of channels open) at a site. A, All-points histogram and representative traces in the presence of 2 mmol/L extracellular Ca 2+ (top) 10 mmol/L extracellular Ca 2+ (middle) and 10 mmol/L extracellular Ca 2+ and 100 mmol/L KCl (bottom). B, All-points histograms in the presence of a TRPV4 channel agonist GSK101 (10 nmol/L, top), a different TRPV4 channel agonist RN1747 (1 mol/L, middle), and with the addition of a TRPV4 channel inhibitor HC067047 (1 mol/L, bottom) in the presence of GSK101. The data were pooled from three PAs for each histogram. n=8, 6, 8, 6, 6, 6, 7, 6 fields from left to right; P<0.0001 using one-way ANOVA; *P<0.05 versus L-NNA). B, Averaged NONOate-dependent change in DAF-FM fluorescence in ECs and SMCs from PAs relative to the fluorescence in the presence of L-NNA (baseline). Data are mean ± SEM (n=6, 8, 6, 6, 8, 6 fields from left to right; P<0.0001 using one-way ANOVA; *P<0.05 versus 3 mol/L NONOate). The dotted blue line indicates GSK101-induced increase in DAF fluorescence in ECs, whereas dotted red line indicates GSK101-induced increase in DAF fluorescence in SMCs. C, Averaged percent dilations of PAs to NONOate (1-30 mol/L; n=7, 9, 9, 9, 9, 6 PAs from left to right; P=0.0077 using one-way ANOVA). 
Video Legend:
Video S1. TRPV4 sparklets in 4 th -order pulmonary arteries (PAs) in an en face preparation. PAs were loaded with fluo-4AM (10 mol/L). Cyclopiazonic acid (CPA, 20 mol/L) was used in order to eliminate the interference from ER Ca 2+ release. The activity of TRPV4 sparklets was increased using TRPV4 channel agonist GSK101 (3 nmol/L).
